New 8-Nitroquinolinone Derivative Displaying Submicromolar <i>in Vitro</i> Activities against Both <i>Trypanosoma brucei</i> and <i>cruzi</i>
作者:Julien Pedron、Clotilde Boudot、Jean-Yves Brossas、Emilie Pinault、Sandra Bourgeade-Delmas、Alix Sournia-Saquet、Elisa Boutet-Robinet、Alexandre Destere、Antoine Tronnet、Justine Bergé、Colin Bonduelle、Céline Deraeve、Geneviève Pratviel、Jean-Luc Stigliani、Luc Paris、Dominique Mazier、Sophie Corvaisier、Marc Since、Aurélie Malzert-Fréon、Susan Wyllie、Rachel Milne、Alan H. Fairlamb、Alexis Valentin、Bertrand Courtioux、Pierre Verhaeghe
DOI:10.1021/acsmedchemlett.9b00566
日期:2020.4.9
position 6 of the 8-nitroquinolin-2(1H)-one pharmacophore. Fifteen new derivatives were synthesized and evaluated in vitro against L. infantum, T. brucei brucei, and T. cruzi, in parallel with a cytotoxicity assay on the human HepG2 cell line. A potent and selective 6-bromo-substituted antitrypanosomal derivative 12 was revealed, presenting EC50 values of 12 and 500 nM on T. b. brucei trypomastigotes and T
在8-硝基喹啉2(1H)-一个药效基团的6位进行了抗运动型药物代谢研究。合成了十五种新衍生物,并在体外针对婴儿L. brucei brucei和T. cruzi进行了评估,同时对人HepG2细胞系进行了细胞毒性试验。揭示了一种有效且选择性的6-溴取代的抗锥虫衍生物12,在T. b上的EC50值为12和500 nM。与四种参比药物(30 nM≤EC50≤13μM)相比,分别为布鲁氏锥虫病和克鲁氏锥虫。此外,化合物12在彗星试验中没有遗传毒性,在口服后小鼠体内显示出很高的体外微粒体稳定性(半衰期> 40分钟)以及良好的药代动力学行为。最后,分子12(E°= -0。